Open Access

Systemic markers of inflammation are independently associated with S100B concentration: results of an observational study in subjects with acute ischaemic stroke

  • Christopher Beer1, 2, 3, 4Email author,
  • David Blacker2, 5,
  • Michael Bynevelt4, 5,
  • Graeme J Hankey2, 4 and
  • Ian B Puddey2, 4
Journal of Neuroinflammation20107:71

https://doi.org/10.1186/1742-2094-7-71

Received: 10 August 2010

Accepted: 29 October 2010

Published: 29 October 2010

Abstract

Background

Vascular dysfunction and brain inflammation are thought to contribute to the pathophysiology of cerebral injury in acute stroke. However acute inflammation and vascular dysfunction may simply be markers of an acute phase response to cerebral injury, reflecting the size of the cerebral lesion. We aimed to determine if systemic markers of vascular dysfunction and inflammation are independently associated with concentrations of the astroglial protein S100B, a marker of brain injury, in participants with acute ischaemic stroke.

Methods

Fifty-seven men and women recruited within 96 hours of acute ischaemic stroke at two tertiary hospitals participated in this cross sectional observational study. Clinical, imaging (stroke lesions area measured with perfusion CT) and laboratory data were the independent variables and co-variates. The outcome variable was serum S100B concentration, analysed by multivariate regression.

Results

High sensitivity-CRP (B = 0.41) and lesion area (B = 0.69) were independently associated with S100B concentration (R2 = 0.75, p < 0.01). Other variables with significant univariate associations with S100B concentration were not independently associated with S100B concentration in the final multivariate model.

Conclusion

The degree of systemic inflammation is associated with S100B concentration in acute ischaemic stroke, independent of the size of the ischaemic lesion.

Background

Acute ischaemic stroke is associated with a rise in systemic markers of endothelial activation, inflammation and oxidative stress [16]. At the site of brain injury vascular dysfunction, oxidative stress and brain inflammation are thought to contribute to the pathophysiology of cerebral injury in acute stroke [2, 7]. However, it is uncertain whether these factors simply represent an "acute phase" response to the cerebral injury, and associated complications such as immobility, or are important independent predictors of the degree of cerebral injury resulting from an acute ischaemic insult.

Much evidence shows that inflammation in the setting of acute ischaemic stroke is associated with infarct size, supporting the hypothesis that inflammation in acute stroke primarily reflects an acute phase response determined by the degree of cerebral injury [1, 8]. However the magnitude of the acute phase response appears to also be independent an predictor of clinical outcome [9]. In patients with lacunar syndromes, who tend to have small volume lesions, progression of neurologic symptoms is associated with markers of the acute phase response [10]. These data suggest that inflammation may be an important independent factor in the pathophysiology of acute ischaemic stroke.

S100B is a peptide derived largely from astrocytes. In normal physiology S100B has multiple local regulatory effects on cell division and metabolism. Ischaemia is associated with raised S100B levels [11, 12]. This is thought to be due to damage to astrocytes. Thus S100B concentrations are marker of the degree and severity of cellular injury in acute ischaemic stroke.

We conducted this study to test the hypothesis that endothelial function, inflammation and oxidative stress are independently associated with the degree of cellular injury in acute ischaemic stroke. We aimed to determine if endothelial function, inflammation and oxidative stress are associated with S100B concentration in acute ischaemic stroke, and in particular if any association is independent of infarct size.

Methods

Design

Cross-sectional observational study.

Setting and participants

Patients were recruited at two teaching hospitals in Perth, Western Australia between May 2005 and November 2008. Patients admitted with acute ischaemic stroke within 96 hours of onset were eligible to participate. Exclusion criteria were: blood glucose level > 13 mmol/L; acute co-morbid condition; creatinine >120 umol/L; haemorrhage seen on initial CT; and history of sensitivity to contrast. Clinical records were reviewed subsequent to the patient's discharge to confirm a final clinical diagnosis of an acute cerebral ischaemic event and classify the clinical syndrome using the Oxfordshire Community Stroke Project classification [13].

Assessments

Clinical characteristics were assessed using the National Institutes of Health Stroke Scale (NIHSS),[14] Modified Barthel Index (MBI) [15] and Modified Rankin Scale (MRS) [16]. Laboratory data were collected to assess S100B concentrations [11], inflammation (C-reactive protein [CRP] and fibrinogen [9]), endothelial activation (E-selectin [1]), endothelial cell damage (Von Willebrand factor [vWF] [1]) and oxidative stress [F2-isoprostanes] [4]). With the exception of F2-isoprostanes, all assays were performed by the PathWest Laboratory Medicine Units at Royal Perth and Sir Charles Gairdner Hospitals, using routine collection and analysis procedures. For analysis of F2-isporostanes, 5 ml of whole venous blood was collected into cold EDTA tubes containing reduced glutathione and centrifuged as soon as possible at 1000 g for 10 min at 4°C. The plasma was protected from oxidation by the addition of butylated hydroxytoluene at a final concentration of 20 μg/ml plasma and stored at -80°C until analysis by gas chromatography/mass spectrometry [17]. Blood pressure was assessed using validated ,[18, 19] oscillometric ambulatory blood pressure monitors (Oscar 2, SunTech Medical, Morrisville NC USA) worn by participants for 24 hours after enrolment.

Participants underwent perfusion CT scanning. Five patients were imaged prior to July 2005. A single 10 mm slice was taken at the level of the third ventricle. Cycle time was 1 s. Subsequent to July 2005 8 slices were acquired on mulitdetector machines (Philips Brilliance 64 slice scanner). 40 mL of non-ionic contrast ('Optiray') was administered over 10 seconds using an intravenous cannula in the antecubital fossa. The multidetector machine protocol was: length 40 mm, thickness 5 mm, increment 0 mm, kV 120, mAs 100, cycle time 1.5, cycles 45, Resolution High, Collimation 32 × 1.25, Rotation time 0.4 sec, Filter Smooth UA, matrix 512. Post processing and analysis was completed on Philips and GE workstations. When multiple slices were available, the slice with greatest lesion area evident on the plain CT was chosen for analysis. Infarct size was measured by an experienced neuroradiologist (MB) blinded to treatment allocation.

Data analysis

SPSS for MS Windows was used to analyse data. Log-normal data were log transformed prior to analysis. Non-normal data were analysed using non parametric tests. Categorical variables were assessed with the chi squares or fisher exact test. Linear regression modeling was used to examine the association between predictor variables and concentration of S100B. Only non-missing data were included in the modeling exercise. This commenced with a series of univariate models to identify all candidate predictor variables. These significant variables were then included in a multivariate logistic regression model and removed using a backward stepwise process if their significance was not retained. Box-plots of the remaining variables were re-inspected to ensure that outlying values were not present, before producing the final parsimonious model.

Ethical considerations

The study was approved by the Royal Perth and Sir Charles Gairdner Hospitals Ethics Committees. Able participants provided written informed consent. If there was uncertainty regarding the person's ability to provide informed consent agreement to study participation was also sought from the person's next of kin. The procedures followed were in accordance with the Helsinki Declaration.

Results

Cohort characteristics

An heterogeneous group of 57 acute ischaemic stroke patients participated in the study (Table 1). The mean age of participants was 68 years. Participants were enrolled a mean of 53 hours after the onset of symptoms. Although there was wide variability in the sample, many participants had moderate - severe stroke (the mean NIH stroke scale score was 10, 40% of participants had a modified Rankin score of 4 or 5 and the mean lesion area was 10 cm2).
Table 1

Cohort characteristics

Variable

Mean ± SD or n(%)

Age (years)

67.8+13.7

Male (%)

39 (68%)

Enrolled (hours)

52.6 ± 21.6

Hypertension

35 (61%)

Atrial fibrillation

10 (18%)

Hypercholesterolaemia

11 (19%)

Diabetes

13 (23%)

Smoking

21 (37%)

Aetiology

 

Large vessel

6 (11%)

Small vessel

8 (14%)

Cardioembolic

24 (42%)

Other

1 (2%)

Unknown

18 (32%)

Syndrome

 

Total anterior circulation

14 (25%)

Partial anterior circulation

26 (46%)

Lacunar

11 (19%)

Posterior circulation

6 (11%)

Systolic blood pressure (mmHg)

142.1 ± 19.3

Diastolic blood pressure (mmHg)

80.2 ± 11.2

NIH stroke scale score

8.5 ± 7.8

Modified Rankin scale score

 

0-3

17 (30%)

4-5

40 (70%)

Modified Barthel index score

39.3 ± 33.9

Glucose (mmol/L)

6.3 ± 1.6

Homocysteine (umol/L)

9.9 ± 3.8

High sensitivity-CRP (mg/L)

15.7 ± 27.9

Fibrinogen (g/L)

4.2 ± 1.2

E-selectin (ng/mL)

30.5 ± 34.0

von Willebrand Factor (%)

158.7 ± 61.6

S100B (ug/L)

0.5 ± 0.8

F2-Isoprostanes (nmol/L)

3.2 ± 4.2

Lesion area (mm2)

1001.9 ± 1359.8

Factors associated with S100B concentrations

Significant univariate associations were found between age, stroke syndrome, neurologic impairment (NIHSS Score), disability (Modified Barthel Index score), lesion area, hs-CRP and serum concentration of S100B. These are shown in Table 2. However, of these factors, only hs-CRP (B = 0.41) and lesion area (B = 0.69) remained independently associated with S100B concentration in the final parsimonious multivariate model. Results of this model are also listed in Table 2. The multivariate model, including 54 participants with no missing data, showed that hs-CRP and lesion area explained the majority of variance in S100B (Adjusted R2 = 0.76, p < 0.01).
Table 2

Univariate and multivariate relationships (S100B as dependent variable) analysed by linear regression

Predictor

B

SE B

B

p

Univariate Relationships

Age

0.01

0.01

0.27

0.05

Gender

-0.10

0.18

-0.07

0.60

Hours to enrolment

0.00

0.00

0.07

0.62

Hypertension

-0.06

0.17

-0.05

0.73

Atrial fibrillation

0.19

0.22

0.12

0.40

Hypercholesterolaemia

-0.20

0.22

-0.12

0.37

Diabetes

0.02

0.20

0.02

0.90

Smoking history

-0.09

0.17

-0.07

0.60

Aetiology

-0.03

0.06

-0.06

0.66

Clinical syndrome

-0.43

0.08

-0.61

0.00

Systolic blood pressure

0.00

0.00

0.00

0.99

Diastolic blood pressure

0.00

0.01

-0.07

0.58

NIHSS score

0.56

0.20

0.36

0.01

Modified Rankin

0.00

0.00

1.10

0.28

Modified Barthel

-0.01

0.00

-0.36

0.01

Glucose

1.52

0.84

0.25

0.08

Homocysteine

0.01

0.52

0.00

0.99

Hs-CRP

0.56

0.12

0.55

0.00

Fibrinogen

0.10

0.07

0.20

0.16

E-Selectin

-0.09

0.29

-0.04

0.75

von Willebrand factor activity

0.00

0.00

2.26

0.03

F2-Isoprostanes

0.04

0.31

0.02

0.89

Lesion area

0.73

0.08

0.77

0.00

Final multivariate model

Hs-CRP

0.42

0.07

0.41

0.00

Lesion area

0.65

0.07

0.69

0.00

Discussion

Main findings

These data show that the relationship between S100B concentration and inflammation in participants with acute ischaemic stroke is independent of infarct size. These data establish an independent association between markers of inflammation and glial injury, suggesting that the inflammatory response to acute ischaemic injury may be a therapeutic target. The concept that limiting inflammation may limit brain injury is supported by evidence that components of the acute phase response to cerebral injury are deleterious. For example, CRP is known to inhibit generation of endothelial progenitor cells, which are necessary for angiogensis [20]. Future intervention studies are required to determine whether modifying the inflammatory response may limit cellular injury in acute ischaemic stroke.

Results in context of other studies

S100B has previously been found to be correlated with CRP in subjects with acute ischaemic stoke at 12, 24 and 72 hours after stroke, after controlling for gender, age and leukocyte count [21]. The present results extend those findings to show that the association between CRP and S100B is also independent of infarct size and a range of other potentially confounding variables.

Since our study was planned there has been an accumulation of data regarding the potential importance of inflammation and S100B concentrations in subjects with acute ischaemic stroke and other neurologic disorders. Both CRP concentrations at 72 hours, and S100B concentrations at twelve hours, have been found to be independently associated with clinical outcome following acute ischaemic stroke [22]. At nano-molar levels S100B has trophic effects which may an adaptive response to brain injury. However S100B at micromolar concentrations, may itself have neurotoxic (apoptotic) effects[23]. Over-expression of S100B has now been documented in a range of brain diseases [23]. Thus, although we were interested in S100B as a surrogate marker of clinical outcome, the higher concentrations of S100B may potentially cause, rather than simply reflecting, the degree of brain injury.

S100B also has pro-inflammatory effects. Although S100B is thought to be brain-specific, raised concentrations of S100B have been observed in systemic diseases without apparent neurologic involvement. Among subjects with systemic lupus erythematosus, concentrations of S100B were elevated (relative to controls) among subjects without central nervous system involvement, although to a lesser extent than among subjects with neurologic or psychiatric manifestations [24]. This could be because S100B is a sensitive marker of sub-clinical neurologic disease. It has since been postulated that S100B may act as an inflammatory mediator in subjects with non-neurologic disease. However S100B was found not to be associated with CRP in renal transplant recipients [25].

Strengths of our study

Ours is one of few studies to simultaneously assess infarct size, clinical variables and systemic markers of inflammation, oxidative stress and vascular function. We used a conservative approach in the modeling exercise. We included both sensitive clinical scales and imaging measures. For example, the NIHSS correlates with infarct volume (r = 0.68) and is a strong predictor of outcome after stroke [26, 27]. Thus substantial residual confounding of the observed association between inflammation and S100B concentrations by lesion severity seems unlikely. We also accounted for the heterogeneity of acute ischaemic stroke syndromes by assessing stroke aetiology and clinical sub-type.

Limitations

There are several limitations to the study. We did not assess for other potential causes of inflammation (such as deep venous thrombosis and pulmonary atelectasis) which may confound the association between neurologic lesions and inflammation. Other potential confounding variables which were not controlled for include the degree of leukoariosis, and medical therapies. Determining lesion volume (rather than lesion size in one plane) would also have allowed greater confidence that differences due to lesion severity were adequately controlled in the multivariate models.

Interpretation of our results is also limited as S100B was only measured once. We were thus unable to account for differences in inflammatory status prior to the acute stroke event. The cross sectional design prevents any causal inferences being made. In addition, elevated S100B concentrations are not specific to ischaemic brain injury and the pattern of change in S100B levels is variable depending on the stroke subtype. Overall, serum S100B levels peak 2-3 days after an ischaemic stroke [12]. However in large middle cerebral artery (MCA) territory strokes serum S100B levels may not peak until 7 days [11]. Despite this variability, single S100B concentrations measured 2-3 days after non-lacunar ischaemic stroke were found to provide optimal predictive value compared to more complex measures [28]. Although S100B consistently appears to predict outcomes, data from subjects with traumatic brain injury indicate that the relationship between inflammation and alternative markers of brain injury (such as neuron specific enolase) may also warrant examination in subjects with acute ischaemic stroke [29].

Conclusion

The degree of systemic inflammation is independently associated with S100B concentrations in subjects with acute ischaemic stroke.

Declarations

Acknowledgements

Funding from the NH&MRC Centre of Clinical Research Excellence - Centre for Training in Clinical Cerebrovascular and Cardiovascular Research is acknowledged. The authors thank Melanie Rosenberg for her assistance with CT scan acquisition. A UWA Research Grant funded S100B assays. A UWA Small Bequest Research Grant funded isoprostane and CRP assays. 'Oscar 2' ambulatory blood pressure monitors were donated by SunTech Medical. Funding sources and donors had no role in the design or conduct of the study. The authors declare that they have no conflicts of interest or disclosures relevant to this work.

Authors’ Affiliations

(1)
Western Australian Centre for Health and Ageing, University of Western
(2)
School of Medicine and Pharmacology, University of Western
(3)
Centre for Medical Research, Western Australian Institute for Medical Research
(4)
Royal Perth Hospital
(5)
Sir Charles Gairdner Hospital

References

  1. Cherian P, Hankey GJ, Eikelboom JW, Thom J, Baker RI, McQuillan A, Staton J, Yi Q: Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke. 2003, 34: 2132-2137. 10.1161/01.STR.0000086466.32421.F4.View ArticlePubMedGoogle Scholar
  2. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999, 22: 391-397. 10.1016/S0166-2236(99)01401-0.View ArticlePubMedGoogle Scholar
  3. Lip GYH, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG: Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagulation & Fibrinolysis. 2002, 13: 339-347.View ArticleGoogle Scholar
  4. Sanchez-Moreno C, Dashe JF, Scott T, Thaler D, Folstein MF, Martin A: Decreased Levels of Plasma Vitamin C and Increased Concentrations of Inflammatory and Oxidative Stress Markers After Stroke. Stroke. 2004, 35: 163-168. 10.1161/01.STR.0000105391.62306.2E.View ArticlePubMedGoogle Scholar
  5. van Kooten F, Ciabattoni G, Patrono C, Dippel DWJ, Koudstaal PJ: Platelet Activation and Lipid Peroxidation in Patients With Acute Ischemic Stroke. Stroke. 1997, 28: 1557-1563.View ArticlePubMedGoogle Scholar
  6. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, del Zoppo GJ, Hallenbeck JM, Rothwell NJ, Hopkins SJ, Tyrrell PJ: Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004, 4: 2-10.1186/1471-2377-4-2.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, Milne GL, Hubbard J, Lee H, Stevenson E, et al: Oxidative Stress and Matrix Metalloproteinase-9 in Acute Ischemic Stroke: The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) Study. Stroke. 2008, 39: 100-104. 10.1161/STROKEAHA.107.488189.View ArticlePubMedGoogle Scholar
  8. Eikelboom JW, Hankey GJ, Baker RI, McQuillan A, Thom J, Staton J, Cole V, Yi Q: C-reactive protein in ischemic stroke and its etiologic subtypes. Journal of Stroke and Cerebrovascular Diseases. 2003, 12: 74-81. 10.1053/jscd.2003.16.View ArticlePubMedGoogle Scholar
  9. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR: C-Reactive Protein and Outcome After Ischemic Stroke. Stroke. 1999, 30: 981-985.View ArticlePubMedGoogle Scholar
  10. Audebert HJ, Pellkofer TS, Wimmer ML, Haberl RL: Progression in lacunar stroke is related to elevated acute phase parameters. Eur Neurol. 2004, 51: 125-131. 10.1159/000077012.View ArticlePubMedGoogle Scholar
  11. Herrmann M, Ehrenreich H: Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor Neurol Neurosci. 2003, 21: 177-190.PubMedGoogle Scholar
  12. Rothermundt M, Peters M, Prehn JH, Arolt V: S100B in brain damage and neurodegeneration. Microsc Res Tech. 2003, 60: 614-632. 10.1002/jemt.10303.View ArticlePubMedGoogle Scholar
  13. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991, 337: 1521-1526. 10.1016/0140-6736(91)93206-O.View ArticlePubMedGoogle Scholar
  14. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al: Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989, 20: 864-870.View ArticlePubMedGoogle Scholar
  15. Shah S, Vanclay F, Cooper B: Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989, 42: 703-709. 10.1016/0895-4356(89)90065-6.View ArticlePubMedGoogle Scholar
  16. Bamford JM, Sandercock PA, Warlow CP, Slattery J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1989, 20: 828.View ArticlePubMedGoogle Scholar
  17. Mori TA, Croft KD, Puddey IB, Beilin LJ: An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. Anal Biochem. 1999, 268: 117-125. 10.1006/abio.1998.3037.View ArticlePubMedGoogle Scholar
  18. Jones SC, Bilous M, Winship S, Finn P, Goodwin J: Validation of the OSCAR 2 oscillometric 24-hour ambulatory blood pressure monitor according to the International Protocol for the validation of blood pressure measuring devices. Blood Press Monit. 2004, 9: 219-223. 10.1097/00126097-200408000-00007.View ArticlePubMedGoogle Scholar
  19. Goodwin J, Bilous M, Winship S, Finn P, Jones SC: Validation of the Oscar 2 oscillometric 24-h ambulatory blood pressure monitor according to the British Hypertension Society protocol. Blood Press Monit. 2007, 12: 113-117. 10.1097/MBP.0b013e3280acab1b.View ArticlePubMedGoogle Scholar
  20. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, et al: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004, 109: 2058-2067. 10.1161/01.CIR.0000127577.63323.24.View ArticlePubMedGoogle Scholar
  21. Worthmann H, Tryc AB, Goldbecker A, Ma YT, Tountopoulou A, Hahn A, Dengler R, Lichtinghagen R, Weissenborn K: The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis. 2010, 30: 85-92. 10.1159/000314624.View ArticlePubMedGoogle Scholar
  22. Sienkiewicz-Jarosz H, Galecka-Wolska M, Bidzinski A, Turzynska D, Sobolewska A, Lipska B, Plaznik A, Ryglewicz D: Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. Neurol Neurochir Pol. 2009, 43: 126-133.PubMedGoogle Scholar
  23. Sen J, Belli A: S100B in neuropathologic states: the CRP of the brain?. J Neurosci Res. 2007, 85: 1373-1380. 10.1002/jnr.21211.View ArticlePubMedGoogle Scholar
  24. Portela LV, Brenol JC, Walz R, Bianchin M, Tort AB, Canabarro UP, Beheregaray S, Marasca JA, Xavier RM, Neto EC, et al: Serum S100B levels in patients with lupus erythematosus: preliminary observation. Clin Diagn Lab Immunol. 2002, 9: 164-166.PubMed CentralPubMedGoogle Scholar
  25. Gross S, Homan van der Heide JJ, van Son WJ, Gans RO, Foell D, Navis G, Bakker SJ: Body mass index and creatinine clearance are associated with steady-state serum concentrations of the cell damage marker S100B in renal transplant recipients. Med Sci Monit. 2010, 16: CR318-324.PubMedGoogle Scholar
  26. Johnston KC, Wagner DP, Haley EC, Connors AF: Combined clinical and imaging information as an early stroke outcome measure. Stroke. 2002, 33: 466-472. 10.1161/hs0202.102881.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Adams HP, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, Woolson RF, Hansen MD: Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999, 53: 126-131.View ArticlePubMedGoogle Scholar
  28. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M: Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol. 2005, 62: 1130-1134. 10.1001/archneur.62.7.1130.View ArticlePubMedGoogle Scholar
  29. Pleines UE, Morganti-Kossmann MC, Rancan M, Joller H, Trentz O, Kossmann T: S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma. 2001, 18: 491-498. 10.1089/089771501300227297.View ArticlePubMedGoogle Scholar

Copyright

© Beer et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement